LOXL2 and hepatocellular carcinoma: In hepatocellular carcinoma, however, LOXL2 increases HIF1 gene expression by counteracting, in an SNAI1-dependent way, the negative action of fructose-1,6-bisphosphatase (FBP1) on HIF1 gene expression, resulting in increased aerobic glycolysis and angiogenesis [124].